Randomized trial · people

Teriparatide: 45.4% of jaw osteonecrosis lesions resolved by 52 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a small controlled trial, a short teriparatide course added to standard care helped more MRONJ lesions resolve than placebo, with mostly mild side effects.

Kind
Randomized trial
Studied in
People
Number studied
34
Published
2020
Journal
J Clin Oncol

What they tested

The team tested whether a short course of teriparatide helps established medication-related osteonecrosis of the jaw (MRONJ, jaw bone damage linked to antiresorptive and antiangiogenic medicines) heal better than placebo.

How the study was done

A double-blind, randomized, placebo-controlled trial in 34 people with established MRONJ, who had 47 separate lesions between them. They got 8 weeks of daily teriparatide shots under the skin (20 µg/day) or placebo shots (a dummy injection), on top of calcium, vitamin D and standard care, and were followed for 12 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Lesions healed at a higher rate in people on teriparatide than in those on placebo. At 52 weeks, 45.4% of teriparatide-treated lesions had resolved, versus 33.3% of lesions on placebo. The teriparatide group also had smaller bony defects at week 52 (odds ratio 8.1). Side effects were about as common in both groups and mostly mild, such as nausea, poor appetite and muscle or bone pain.

What it doesn’t show

This was a small trial of 34 people with one 8-week treatment course and 12 months of follow-up. Results were counted per lesion, and everyone also got calcium, vitamin D and standard care.

The paper

Sim et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol. 2020.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo